Targeting Dendritic Cell Function during Systemic Autoimmunity to Restore Tolerance
Open Access
- 16 September 2014
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (9) , 16381-16417
Abstract
Systemic autoimmune diseases can damage nearly every tissue or cell type of the body. Although a great deal of progress has been made in understanding the pathogenesis of autoimmune diseases, current therapies have not been improved, remain unspecific and are associated with significant side effects. Because dendritic cells (DCs) play a major role in promoting immune tolerance against self-antigens (self-Ags), current efforts are focusing at generating new therapies based on the transfer of tolerogenic DCs (tolDCs) during autoimmunity. However, the feasibility of this approach during systemic autoimmunity has yet to be evaluated. TolDCs may ameliorate autoimmunity mainly by restoring T cell tolerance and, thus, indirectly modulating autoantibody development. In vitro induction of tolDCs loaded with immunodominant self-Ags and subsequent cell transfer to patients would be a specific new therapy that will avoid systemic immunosuppression. Herein, we review recent approaches evaluating the potential of tolDCs for the treatment of systemic autoimmune disorders.Keywords
This publication has 234 references indexed in Scilit:
- A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokinesJournal of Translational Medicine, 2013
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- Rapamycin-conditioned, alloantigen-pulsed myeloid dendritic cells present donor MHC class I/peptide via the semi-direct pathway and inhibit survival of antigen-specific CD8+ T cells in vitro and in vivoTransplant Immunology, 2011
- Dendritic Cells in Lupus Are Not Required for Activation of T and B Cells but Promote Their Expansion, Resulting in Tissue DamageImmunity, 2010
- Macrophages Expressing Heme Oxygenase-1 Improve Renal Function in Ischemia/Reperfusion InjuryMolecular Therapy, 2010
- B7‐1/2, but not PD‐L1/2 molecules, are required on IL‐10‐treated tolerogenic DC and DC‐derived exosomes for in vivo functionEuropean Journal of Immunology, 2009
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signalNature Immunology, 2009
- PD‐1 ligands expressed on myeloid‐derived APC in the CNS regulate T‐cell responses in EAEEuropean Journal of Immunology, 2008
- Development of autoimmune hepatitis–like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuatorArthritis & Rheumatism, 2008
- RETRACTED ARTICLE: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRILNature Immunology, 2002